PGC-1α调控高血压的机制研究及中药干预的研究进展  

Mechanism of PGC-1α Regulating Hypertension and Chinese Medicine Intervention:A Review

作　　者：邓林华 蔡晓月[2] 赵英强[2] 柳威[2] Deng Linhua;Cai Xiaoyue;Zhao Yingqiang;Liu Wei(Graduate School of Tianjin University of Traditional Chinese Medicine,Tianjin 301617;Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin 300150)

机构地区：[1]天津中医药大学研究生院,天津301617 [2]天津中医药大学第二附属医院,天津300150

出　　处：《中药药理与临床》2022年第5期208-212,共5页Pharmacology and Clinics of Chinese Materia Medica

基　　金：国家自然科学基金项目(编号:81803890)。

摘　　要：高血压是世界上最常见的慢性疾病之一,其发病机制复杂。线粒体作为全身的供能结构,接受细胞内外的刺激从而产生各种重要的调节信号,与高血压之间存在着千丝万缕的联系。PGC-1α是线粒体生物合成的关键调节因子,为了进一步明确PGC-1α在高血压中的调控作用及中医药干预的作用,本文综述了相关的研究进展。大量的研究证实,PGC-1α通过氧化应激、炎症反应、胰岛素抵抗等途径参与了高血压的发生发展,对心血管系统具有保护作用,中医药可以通过PGC-1α改善氧化应激和线粒体功能障碍发挥降压作用,从而改善心脏功能。本综述为中药通过PGC-1α发挥降压作用的相关机制研究提供了部分参考。Hypertension,a global common chronic disease,features complicated pathogenesis.As powerhouses of the body,mitochondria synthesize various important regulatory signals in response to intercellular or intracellular stimuli,which are closely related to hypertension.PGC-1αis a key regulator synthesized by mitochondria.This study reviewed the mechanism of PGC-1αregulating hypertension and Chinese medicine intervention and drew the following conclusions.PGC-1αparticipates in the occurrence and development of hypertension through oxidative stress,inflammatory response,and insulin resistance,and protects the cardiovascular system.Chinese medicine lowers blood pressure by improving oxidative stress and mitochondrial dysfunction through PGC-1α,thus improving cardiac function.

关 键 词：过氧化物酶体增殖物激活受体γ共激活因子1(PGC-1α) 线粒体 高血压 中医药 

分 类 号：R285[医药卫生—中药学]